Literature DB >> 6137390

Electrophysiological demonstration of both alpha 2-agonist and antagonist properties of RX 781094.

J M Goldstein, L C Knobloch, J B Malick.   

Abstract

The effects of RX 781094, a new and potent alpha 2-adrenoceptor antagonist, on locus coeruleus (LC) unit activity were examined. Low doses of RX 781094 produced suppression of spontaneous LC unit activity which could be reversed with yohimbine. The increase in LC firing produced by WB 4101 could also be reversed with a low dose of RX 781094. Thus, at low doses, RX 781094 has clonidine-like alpha 2-agonist activity. At higher doses, RX 781094 reversed the effects of clonidine and markedly shifted the dose of clonidine required to suppress LC unit activity. These data suggest that at high doses RX 781094 has alpha 2-antagonist properties. It is concluded that RX 781094 may be a partial agonist at alpha 2-adrenoceptors in the CNS.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137390     DOI: 10.1016/0014-2999(83)90368-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons.

Authors:  Elsa Isingrini; Léa Perret; Quentin Rainer; Bénédicte Amilhon; Elisa Guma; Arnaud Tanti; Garance Martin; Jennifer Robinson; Luc Moquin; Fabio Marti; Naguib Mechawar; Sylvain Williams; Alain Gratton; Bruno Giros
Journal:  Nat Neurosci       Date:  2016-02-15       Impact factor: 24.884

2.  Evidence that serotonin receptors are involved in the anticonvulsant effect of yohimbine in mice.

Authors:  N Ludvig; L György; E S Vizi
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Antagonism by idazoxan at low dose but not high dose, of the natriuretic action of moxonidine.

Authors:  D R Allan; S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

4.  Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine.

Authors:  J C Doxey; A C Lane; A G Roach; N K Virdee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

5.  Evidence for a peripheral component in the sympatholytic effect of clonidine in rats.

Authors:  M J Brown; D Harland
Journal:  Br J Pharmacol       Date:  1984-11       Impact factor: 8.739

6.  Alpha-adrenoceptor antagonists and the release of noradrenaline in rabbit cerebral cortex slices: support for the alpha-autoreceptor hypothesis.

Authors:  P Heepe; K Starke
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

7.  Dopaminergic modulation of hippocampal noradrenaline release. Evidence for alpha 2-antagonistic effects of some dopamine receptor agonists and antagonists.

Authors:  R Jackisch; S Moll; T J Feuerstein; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

8.  The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo.

Authors:  J C van Oene; J B de Vries; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-10       Impact factor: 3.000

9.  Possible involvement of presynaptic alpha 1-adrenoceptors in the effects of idazoxan and prazosin on 3H-noradrenaline release from tail arteries of SHR.

Authors:  P E Hicks; M Najar; M Vidal; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-08       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.